Clinical P pharmaphorum
AZ and Oracle team up on AI platform for clinical trials
AZ and Oracle team up on AI platform for clinical trials Phil.Taylor Tue, 20/10/2026 - 11:03
Clinical headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Clinical P pharmaphorum
AZ and Oracle team up on AI platform for clinical trials Phil.Taylor Tue, 20/10/2026 - 11:03
Clinical
Clinical Trials Arena
The biotech is now hoping that duravyu will have more success in DME, with pivotal readouts expected late next year. The post EyePoint halves workforce and ends Phase III trial early after endpoint miss appeared first on Clinical Trials Arena.
Clinical P Pharmafile
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an experimental oral therapy targeting acute myeloid leukaemia (AML) and high-risk myelodysplastic syndromes (MDS). The BRAMLIE trial will assess the safety, pharmacokinetics and preliminary efficacy…
Clinical
European Biotechnology
Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers cancer vaccine follow-up, changes to kidney and obesity trials, and two developments in AI-enabled drug discovery. Here are six updates worth catching up on. The post Ev…
Clinical S Science News
Study will first test a “mismatched” vaccine, but Bundibugyo-specific shots may be added as early as next month
Clinical N Nature Medicine
Clinical
BioCentury
BIOCENTURY | DISCOVERY & TRANSLATIONCOULD A METABOLIC LENS ON MORTALITY RESHAPE CLINICAL TRIALS?The metabolic vulnerability index captures overlooked mortality risk, with stronger predictions of death than disease onset
Clinical
BioSpace
EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.
Clinical
Clinical Trials Arena
Veradermics said that its drug could be the first approved by the FDA for male hair loss in almost three decades. The post Veradermics’ stock up on male hair loss trial success appeared first on Clinical Trials Arena.
Clinical B BioPharm International
Cemiplimab's proposed EU regimen could cut Libtayo infusion visits from every 3 weeks to every 6 weeks, trimming infusion time by up to half.
Clinical
Clinical Trials Arena
Meghna Rajesh, senior research analyst for Beroe Inc., discusses how RTCT will impact supply chains and how sponsors need to consider that now. The post Real-time clinical trials: what it means for procurement strategy appeared first on Clinical Trials Arena.
Clinical A Applied Clinical Trials
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening the distance between signals, human judgment, and the next best action.
Clinical
Bio.News
America’s biotech industry has facilitated 50 years of innovative breakthroughs that have changed the landscape of healthcare as we know it—offering the promise of […] The post PACE: BIO’s 15th annual patient advocacy event focuses on access appeared first on Bio.News.
Clinical
European Biotechnology
French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial. However, the results are similar to those previously achieved with Tedopi alone, r…
Clinical
STAT Biotech
An oral treatment from Gilead Sciences eliminated the symptoms experienced by patients with a type of inflammatory bowel disease, according to mid-stage study results reported Monday.
Clinical
Clinical Trials Arena
Cyrano Therapeutics has reported that the Phase II FLAVOR study of CYR-064 met its primary safety endpoint in patients with hyposmia. The post Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint appeared first on Clinical Trials Arena.
Clinical P pharmaphorum
Novartis abandons Fabhalta trial in lupus nephritis Phil.Taylor Sun, 18/10/2026 - 19:55
Clinical
GEN
HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells. The post Diasome’s HDV-Insulin for T1D Finalizing Pha…
Clinical A Applied Clinical Trials
ProofPilot’s Lauren Briggs talks on why sponsors and CROs fail at tech rollouts by skipping change management, and pushes for the industry to judge trial technology by real workflow impact rather than feature checklists.
Clinical A Applied Clinical Trials
Trially CEO Kyle McAllister explains why transparent AI reasoning is essential for trial patient matching.
Clinical A Applied Clinical Trials
Trially Co-founder and CEO Kyle McAllister, explains how AI absorbing the bulk of clinical-trial chart reviews can free research sites to focus staff time on higher-value tasks.
Clinical B BioPharm International
Interim phase 1/2 data presented at Retina in Rio 2026 showed sustained visual improvements with Opus Genetics’ AAV8 gene therapy OPGx-LCA5 and improved retinal sensitivity with OPGx-BEST1 in inherited retinal diseases.
Clinical
PharmaVoice
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
Clinical
European Biotechnology
French-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, which achieved a nonsignificant efficacy estimate of 24% against a predefined target of 50%. The company is now emphasizing a strategy to combine its candida…
Clinical
Clinical Trials Arena
MacroGenics has dosed the first patient in a Phase I study of its investigational therapy, MGC030, for advanced solid tumours. The post First patient dosed in MacroGenics’ Phase I MGC030 trial appeared first on Clinical Trials Arena.
Clinical
Clinical Trials Arena
Merz Therapeutics has concluded patient enrolment in MINT-C and MINT-E, two global Phase III clinical trials assessing Xeomin for adult migraine prevention. The post Merz concludes enrolment in Phase III Xeomin trials for migraine appeared first on Clinical Trials Arena.
Clinical N Nature Medicine
Clinical
Fierce Biotech
Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions scox Thu, 10/15/2026 - 16:06
Clinical A Applied Clinical Trials
Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the desi…
Clinical
Fierce Pharma
The Next Chapter for AI in Clinical Trials lbarrick Thu, 10/15/2026 - 13:31
Clinical
Fierce Pharma
Why Are 53% of Phase 2 and 3 Trials Delayed? A Redesign Is Overdue jpiatt Thu, 10/15/2026 - 12:32
Clinical
STAT Biotech
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
Clinical
C&EN Pharmaceuticals
Prediction markets are wagering on clinical trials. Should scientists participate?
Clinical A Applied Clinical Trials
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavio…
Clinical
Clinical Trials Arena
This comes as many pharma companies fail to crack the SAD indication, with little innovation seen in the space in recent years. The post Vanda puts anxiety drug’s development on ice after Phase III fail appeared first on Clinical Trials Arena.
Clinical
Clinical Trials Arena
Spinogenix has broadened its ongoing Phase IIb/III CLARITY basket trial to include a Phase IIb study of codabakalner in idiopathic ASD. The post Spinogenix adds Phase IIb autism study to CLARITY basket trial appeared first on Clinical Trials Arena.
Clinical P pharmaphorum
Why clinical trials lose a quarter of their patients before enrolment Nicole.Raleigh Thu, 15/10/2026 - 09:00
Clinical
Clinical Trials Arena
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing PLT012, an investigational therapy for HCC. The post Pilatus doses first patient in Phase I PLT012 trial for HCC appeared first on Clinical Trials Arena.
Clinical P pharmaphorum
Beyond recruitment: Creating patient engagement that lasts Eloise.McLennan Thu, 15/10/2026 - 07:00
Clinical B BioPharm International
The FDA launches a new rare disease development initiative, BioNTech’s BNT113 misses a progression-free survival endpoint, and Viking Therapeutics begins Phase III trials of its oral obesity candidate.